Clinical data | |
---|---|
Trade names | Tebron |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C3H3BrF4 |
Molar mass | 194.955 g·mol−1 |
3D model ( JSmol) | |
| |
|
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed. [1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane. [2] [3] [4]
Clinical data | |
---|---|
Trade names | Tebron |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C3H3BrF4 |
Molar mass | 194.955 g·mol−1 |
3D model ( JSmol) | |
| |
|
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed. [1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane. [2] [3] [4]